https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-07-10 08:37:152025-07-10 08:37:37Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-07-10 08:37:152025-07-10 08:37:37Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
Series A co-led by founding investor M Ventures and new lead…

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson’s Disease
Infudopa SubC® is a user-friendly and minimally invasive alternative…

Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio
Copenhagen, Denmark, 01 July 2025 – Vesper Bio ApS (“Vesper”…

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence
The 2025 Novo Nordisk Foundation Challenge Programme awards DKK…

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer
26 June 2025, Cambridge, UK: STORM Therapeutics Ltd. (STORM),…

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize
Awarded in recognition of excellence in research and innovation…

New Danish research centre to make designed proteins with vast potential
Designed proteins are anticipated to have groundbreaking impact…

Breye Therapeutics announces successful completion of its Phase 1b trial with danegaptide in patients with diabetic retinopathy
Orally administered treatment was well tolerated, with early…

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease
Atrogi’s breakthrough discovery enables chronic use of…

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading International Neurology Experts as it Advances First-in-Class Remyelination Therapy
Professors Shiv Saidha, Cristina Granziera, David Leppert,…

Sofinnova Partners collaborates with NVIDIA to accelerate European life sciences startups
Delivers high-performing AI infrastructure through NVIDIA…

SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
Financing co-led by new investors EQT Life Sciences and Sanofi…

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria
ALY-301 is a first-in-class bispecific antibody targeting…

AMSilk enters Consumer Care Market with the launch of AMSilk4Shine and AMSilk4Care
Neuried, Germany, 10 June 2025 – AMSilk, a global leader in…

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board
Industry and scientific experts in molecular biology, immunology…

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy
Highly experienced biopharma executive Dr Cristina Csimma joins…

Amber Implants Announces Successful One-Year Follow-Up Data in First-in-Human Clinical of VCFix® Spinal System
One-year follow-up data from first-in-human trial shows significant…

iOnctura bolsters leadership team with new appointments
Steven Sciuto joins as Chief Financial Officer (CFO) bringing…

Bionical Emas and Pharma Resources Announce Exclusive Global Clinical Trial Supply Partnership
Strategic agreement secures access to essential oncology injectables…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York